Insulin glargine 300 safe, effective in seniors with T2DM

June 26, 2018

(HealthDay)—For older adults, insulin glargine 300 units/mL (Gla-300) is safe and as effective as Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, according to a study published online June 12 in Diabetes Care.

Robert Ritzel, M.D., from Städtisches Klinikum München GmbH in Munich, Germany, and colleagues conducted a multicenter trial involving , aged ≥65 years, designed to have about 20 percent of participants be aged ≥75 years. A total of 1,014 participants were randomly allocated to receive Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5 to 7.2 mmol/L.

The researchers found that from baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥75 years. Similar and low incidence and rates of confirmed or severe hypoglycemia events were reported between the groups, with lower rates of documented symptomatic hypoglycemia with Gla-300. Compared with the overall population, the subgroup aged ≥75 years had a more apparent lower risk of hypoglycemia with Gla-300 versus Gla-100. The annualized rates of documented symptomatic were significantly lower with Gla-300 (Gla-300, 1.12 versus Gla-100, 2.71; rate ratio, 0.45).

"Gla-300 demonstrated good efficacy and safety in older people with type 2 diabetes, particularly in those of advanced age (≥75 years)," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Sanofi, which funded the study and the clinical trial considered in the analysis.

Explore further: Severe hypoglycemia rates have equilibrated for DCCT groups

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Severe hypoglycemia rates have equilibrated for DCCT groups

June 7, 2017
(HealthDay)—Rates of severe hypoglycemia have equilibrated between the two Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) treatment groups in association ...

Mini-dose glucagon may halt post-exercise hypoglycemia

May 30, 2018
(HealthDay)—Mini-dose glucagon (MDG) is an effective approach for preventing exercise-induced hypoglycemia in patients with type 1 diabetes, according to a study published online May 18 in Diabetes Care.

Studies compare types of insulin for reducing episodes of low blood sugar for patients with Type 1 or 2 diabetes

July 3, 2017
Treatment with the insulin degludec compared to glargine U100 for 32 weeks resulted in a reduced rate of hypoglycemic (low blood sugar) episodes among patients with type 1 or 2 diabetes and at least one risk factor for hypoglycemia, ...

Insulin glargine 300 U/mL beats glargine 100 U/mL in T1DM

January 31, 2017
(HealthDay)—For patients with type 1 diabetes, receipt of insulin glargine 300 U/mL (Gla-300) is associated with better glucose control than glargine 100 U/mL (Gla-100), regardless of injection time, according to a study ...

Differences in arrhythmic risk in nocturnal, daytime hypoglycemia

February 28, 2017
(HealthDay)—For young adults with type 1 diabetes, there are differences in arrhythmic risk and cardiac repolarization during nocturnal versus daytime hypoglycemia, according to a study published online Feb. 17 in Diabetes ...

Dual-hormone system may lower time in hypoglycemia in T1DM

May 16, 2018
(HealthDay)—For physically active adults with type 1 diabetes, the addition of glucagon delivery to a closed-loop system using wearable sensors with automated exercise detection is associated with reduced hypoglycemia, ...

Recommended for you

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.